scispace - formally typeset
P

Pantep Angchaisuksiri

Researcher at Mahidol University

Publications -  111
Citations -  5555

Pantep Angchaisuksiri is an academic researcher from Mahidol University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 31, co-authored 93 publications receiving 3972 citations.

Papers
More filters
Journal Article

Thrombosis: a major contributor to the global disease burden

TL;DR: VTE associated with hospitalization was the leading cause of disability-adjusted life-years lost in low- and middle- income countries, and second in high-income countries, responsible for more disability- adjusted life- years lost than nosocomial pneumonia, catheter-related blood stream infections, and adverse drug events.
Journal ArticleDOI

2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer.

Dominique Farge, +98 more
- 01 Oct 2019 - 
TL;DR: The 2019 International Initiative on Thrombosis and Cancer clinical practice guidelines, which are based on a systematic review of the literature published up to December, 2018, are presented along with a Grading of Recommendations Assessment Development and Evaluation scale methods.
Journal ArticleDOI

Thrombosis: a major contributor to global disease burden

TL;DR: VTE associated with hospitalization was the leading cause of disability-adjusted-life-years lost in low- and middle-income countries, and second in high- income countries, responsible for more DALYs lost than nosocomial pneumonia, catheter-related blood stream infections, and adverse drug events.
Journal ArticleDOI

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19.

TL;DR: The evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for thromboprophylaxis for patients with COVID-19-related critical illness and acute illness who do not have confirmed or suspected venous thromboembolism (VTE) as mentioned in this paper.